Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Consensus Target Price from Analysts
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have received a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the […]
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have received a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the […]
